Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline

Odyssey voyages to Nasdaq with $304M IPO to fund autoimmune, inflammatory pipeline is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

James Waldron · 2026-05-08

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO this morning.

Source: FierceBiotech